Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Zymeworks BC Inc (NASDAQ: ZYME) was $24.18 for the day, down -5.10% from the previous closing price of $25.48. In other words, the price has decreased by -$5.10 from its previous closing price. On the day, 1.74 million shares were traded. ZYME stock price reached its highest trading level at $25.32 during the session, while it also had its lowest trading level at $23.71.
Ratios:
Our analysis of ZYME’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 6.94. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On December 03, 2025, Citizens JMP started tracking the stock assigning a Mkt Outperform rating and target price of $32.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 05 ’26 when Smith Jeffrey T L sold 10,538 shares for $25.10 per share. The transaction valued at 264,471 led to the insider holds 18,352 shares of the business.
Galbraith Kenneth sold 54,343 shares of ZYME for $1,363,841 on Jan 05 ’26. The Chair & CEO now owns 158,286 shares after completing the transaction at $25.10 per share. On Jan 05 ’26, another insider, Moore Paul Andrew, who serves as the Chief Scientific Officer of the company, sold 20,110 shares for $25.10 each. As a result, the insider received 504,699 and left with 31,212 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 1831281664 and an Enterprise Value of 1576518400. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.56 while its Price-to-Book (P/B) ratio in mrq is 5.72. Its current Enterprise Value per Revenue stands at 11.723 whereas that against EBITDA is -25.856.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.25, which has changed by 0.80325544 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $28.49, while it has fallen to a 52-week low of $9.03. The 50-Day Moving Average of the stock is 3.04%, while the 200-Day Moving Average is calculated to be 50.44%.
Shares Statistics:
ZYME traded an average of 1.14M shares per day over the past three months and 658460 shares per day over the past ten days. A total of 75.14M shares are outstanding, with a floating share count of 72.86M. Insiders hold about 3.38% of the company’s shares, while institutions hold 99.56% stake in the company. Shares short for ZYME as of 1765756800 were 3938970 with a Short Ratio of 3.45, compared to 1763078400 on 8541535. Therefore, it implies a Short% of Shares Outstanding of 3938970 and a Short% of Float of 7.71.
Earnings Estimates
The company has 10.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.09, with high estimates of $0.55 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$0.13 and -$1.25 for the fiscal current year, implying an average EPS of -$0.87. EPS for the following year is $0.27, with 11.0 analysts recommending between $3.76 and -$1.52.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 10 analysts. It ranges from a high estimate of $59M to a low estimate of $1.2M. As of. The current estimate, Zymeworks BC Inc’s year-ago sales were $31.03MFor the next quarter, 10 analysts are estimating revenue of $24.2M. There is a high estimate of $29.8M for the next quarter, whereas the lowest estimate is $14.58M.
A total of 12 analysts have provided revenue estimates for ZYME’s current fiscal year. The highest revenue estimate was $162.09M, while the lowest revenue estimate was $104.5M, resulting in an average revenue estimate of $122.89M. In the same quarter a year ago, actual revenue was $76.3MBased on 12 analysts’ estimates, the company’s revenue will be $254.36M in the next fiscal year. The high estimate is $502.1M and the low estimate is $96.08M.
